GMC 252

Drug Profile

GMC 252

Alternative Names: GMC-252; GMC-252-L-lysine salt

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmedica Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Antioxidants; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • Preclinical Dyslipidaemias

Most Recent Events

  • 12 Oct 2017 Genmedica Therapeutics terminates a phase I trial in Healthy volunteers in United Kingdom as the study met its objective by dosing of 13 patients instead of 15 patients (NCT02744820)
  • 15 Dec 2016 Biomarkers information updated
  • 15 Apr 2016 Genmedica Therapeutics plans a phase I trial for Type-2 diabetes mellitus in United Kingdom (PO) (NCT02744820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top